J&J, Medivir gain FDA OK for new hep C therapy simeprevir

John Carroll

Johnson & Johnson and its partner won a green light from the FDA late on Friday to begin marketing their hepatitis C drug , which will now be sold as Olysio. 

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS